Objectives: To assess the immunogenicity and safety of a new candidate, fully liquid, hexavalent DTaP-IPV-Hep B-PRP-T vaccine (Hexaxim, an AcXim family vaccine) compared to a licensed hexavalent DTaP-IPV-Hep B// PRP-T vaccine (Infanrix hexa ) in Peru.
No takes yet. Share an insight, caveat, or question.
Lanata et al. (2012) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: